ArticleBlood2016
Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor.
Article in Blood, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 86 citations in OpenAlex.
- Trial
- Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel.Cell reports. Medicine · 2021Trial
- Ticagrelor IncreasesInternational journal of molecular sciences · 2020Trial
- Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects.European journal of clinical pharmacology · 2018Trial
- Diffuse Alveolar Hemorrhage Mimicking Pneumonia in a Patient With Interstitial Lung Disease on Ticagrelor.Cureus · 2026Article
- Ticagrelor-induced sinus pause: an adenosine-driven side effect.BMJ case reports · 2026Article
- High-throughput combinatorial screening of antiplatelet drugs for personalized medicine.Microsystems & nanoengineering · 2026Article
- A disrupted adenosinergic axis facilitates platelet activation in APS: exploring a novel therapeutic target.Blood advances · 2025Article
- Platelet Activation Pathways Controlling Reversible Integrin αIIbβ3 Activation.TH open : companion journal to thrombosis and haemostasis · 2024Article
- Pharmacological characterization of P2Y receptor subtypes - an update.Purinergic signalling · 2024Review
- Progress in the clinical effects and adverse reactions of ticagrelor.Thrombosis journal · 2024Review
- Ticagrelor inverse agonist activity at the P2YBritish journal of pharmacology · 2024Article
- Review
- Detection of cellular traction forces via the force-triggered Cas12a-mediated catalytic cleavage of a fluorogenic reporter strand.Nature biomedical engineering · 2023Article
- A Case of Ticagrelor-Induced Sinus Pause.Cureus · 2023Article
- Impact of renal function on Ticagrelor-induced antiplatelet effects in coronary artery disease patients.International journal of cardiology. Heart & vasculature · 2023Article
- Platelets and Cardioprotection: The Role of Nitric Oxide and Carbon Oxide.International journal of molecular sciences · 2023Review
- Purinergic signaling in myocardial ischemia-reperfusion injury.Purinergic signalling · 2023Review
- Platelet P2YBMC biology · 2023Article
- Unveiling tumor immune evasion mechanisms: abnormal expression of transporters on immune cells in the tumor microenvironment.Frontiers in immunology · 2023Review
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
Ticagrelor is a potent antagonist of the P2Y
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.